SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS

SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS

ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PAUL EDWARD FLOREANCIG, ELISABETH ANDREE SCHMITTLING, ROBERT DELANE DILLARD, STEPHEN RICHARD BAKER, MICHAEL JOSEPH SOFIA, JASON SCOTT SAWYER
Format: Patent
Sprache:eng
Schlagworte:
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISEASES OR CONDITIONS CHARACTERIZED BY EXCESSIVE RELEASE OF LEUKOTRIENE B4, ONE OF THE METABOLITES OF ARACHIDONIC ACID. THE PRIMARY LTB4 ANTAGONISTIC STRUCTURES ARE REPRESENTED AS: WHEREIN RL, R2, R3, R41 X, Y, Z, AND A ARE DESCRIBED IN DETAIL IN THIS APPLICATION. THIS INVENTION ALSO PROVIDES A PROCESS FOR PREPARING INTERMEDIATE COMPOUNDS OF THE FORMULA XI: WHEREIN R21, R22, AND R23 AND T ARE AS DESCRIBED IN THIS APPLICATION.